Prediction and benefits of minimal disease activity in patients with psoriatic arthritis and active skin disease in the ADEPT trial

Prediction and benefits of minimal disease activity in patients with psoriatic arthritis and active skin disease in the ADEPT trial

To determine the proportion of patients with psoriatic arthritis in the Adalimumab Effectiveness in Psoriatic Arthritis trial achieving minimal disease activity (MDA) and its individual components at 1 or more visits over 144 weeks, identify baseline predictors of MDA achievement, and evaluate the a...

Bibliografski detalji
Glavni autori:	Mease, P, Kavanaugh, A, Coates, L, McInnes, I, Hojnik, M, Zhang, Y, Anderson, J, Dorr, A, Gladman, D
Format:	Journal article
Jezik:	English
Izdano:	BMJ Publishing Group 2017

Slični predmeti

Measurement properties of the minimal disease activity criteria for psoriatic arthritis
od: Coates, L, i dr.
Izdano: (2019)

Deucravacitinib, a selective, TYK2 inhibitor, in psoriatic arthritis: achievement of minimal disease activity components in a phase 2 trial
od: Kavanaugh, A, i dr.
Izdano: (2024)

The benefits and challenges of setting up a longitudinal psoriatic arthritis database
od: Gladman, DD, i dr.
Izdano: (2018)

Treatment to target in psoriatic arthritis with apremilast: probability of achieving targets and comprehensive control of disease manifestations
od: Mease, PJ, i dr.
Izdano: (2020)

Radiographic efficacy of adalimumab in patients with psoriatic arthritis according to demographics, baseline clinical status, methotrexate use and clinical response: subanalysis of adept
od: Choy, E, i dr.
Izdano: (2007)

Withdrawing ixekizumab in patients with psoriatic arthritis who achieved minimal disease activity: results from a randomized, double-blind withdrawal study
od: Coates, LC, i dr.
Izdano: (2021)

Adalimumab treatment with and without methotrexate in patients with moderate to severe psoriatic arthritis: Results from adept
od: Kavanaugh, A, i dr.
Izdano: (2005)

Continuous improvement through differential trajectories of individual minimal disease activity criteria with guselkumab in active psoriatic arthritis: post hoc analysis of a phase 3, randomized, double-blind, placebo-controlled study
od: Coates, LC, i dr.
Izdano: (2024)

Inhibition of radiographic progression in psoriatic arthritis by adalimumab independent of the control of clinical disease activity
od: Landewé, R, i dr.
Izdano: (2019)

Psoriatic arthritis
od: FitzGerald, O, i dr.
Izdano: (2021)

Inhibition of interleukin-17 in patients with oligoarticular psoriatic arthritis
od: Ogdie, A, i dr.
Izdano: (2023)

Assessing structural damage progression in psoriatic arthritis and its role as an outcome in research
od: Désirée van der Heijde, i dr.
Izdano: (2020-02-01)

Classification and outcome measures for psoriatic arthritis
od: Leung, Y, i dr.
Izdano: (2018)

Measuring outcomes in psoriatic arthritis
od: Ogdie, A, i dr.
Izdano: (2020)

Continuous improvement through differential trajectories of individual minimal disease activity criteria with guselkumab in active psoriatic arthritis: post hoc analysis of a phase 3, randomized, double-blind, placebo-controlled study
od: Laura C. Coates, i dr.
Izdano: (2024-02-01)

Considerations for the definition of remission criteria in psoriatic arthritis
od: Mease, P, i dr.
Izdano: (2017)

Effect of secukinumab on the different GRAPPA-OMERACT core domains in psoriatic arthritis: a pooled analysis of 2049 patients
od: Orbai, A-M, i dr.
Izdano: (2019)

Inhibition of Interleukin-17 in Patients with Oligoarticular Psoriatic Arthritis
od: Alexis Ogdie, i dr.
Izdano: (2023-05-01)

Assessing disease activity in psoriatic arthritis: a literature review
od: Tucker, L, i dr.
Izdano: (2018)

Classification and Outcome Measures for Psoriatic Arthritis
od: Ying Ying Leung, i dr.
Izdano: (2018-09-01)

GRAPPA 2021 treatment recommendations for psoriatic arthritis
od: Soriano, ER, i dr.
Izdano: (2023)

New GRAPPA and EULAR recommendations for the management of psoriatic arthritis
od: Coates, L, i dr.
Izdano: (2017)

Residual inflammation in psoriatic arthritis patients in stable minimal disease activity
od: Pierluigi Macchioni, i dr.
Izdano: (2022-12-01)

Methotrexate in psoriasis and psoriatic arthritis
od: Coates, L, i dr.
Izdano: (2020)

Impact of clinical domains other than arthritis on composite outcomes in psoriatic arthritis: comparison of treatment effects in the SEAM-PsA trial
od: Helliwell, PS, i dr.
Izdano: (2022)

Tapering and discontinuation of biologics in patients with psoriatic arthritis with low disease activity
od: Ye, W, i dr.
Izdano: (2018)

Sustained very low disease activity and remission in psoriatic arthritis patients
od: Lubrano, E, i dr.
Izdano: (2019)

Association between patient perception of disease status and different components of the Minimal Disease Activity (MDA) criteria in psoriatic arthritis
od: Yazji, SM, i dr.
Izdano: (2025)

The effect of secukinumab on patient-reported outcomes in patients with active psoriatic arthritis in a randomised phase 3 trial
od: Strand, V, i dr.
Izdano: (2022)

Sustained Very Low Disease Activity and Remission in Psoriatic Arthritis Patients
od: Ennio Lubrano, i dr.
Izdano: (2019-08-01)

Identification of the Minimal Disease Activity Domains Achieved Based on Different Treatments in Psoriatic Arthritis
od: Silvia Scriffignano, i dr.
Izdano: (2023-09-01)

Relationships between psoriatic arthritis composite measures of disease activity with patient-reported outcomes in Phase 3 studies of tofacitinib
od: Coates, L, i dr.
Izdano: (2021)

Achieving minimal disease activity in psoriatic arthritis predicts meaningful improvements in patients’ health-related quality of life and productivity
od: Coates, L, i dr.
Izdano: (2018)

A randomized, phase 3, double-blind trial examining methotrexate and etanercept as monotherapy or in combinstion for treating psoriatic arthritis: A comparison of the composite measures used to evaluate disease activity
od: Mease, PJ, i dr.
Izdano: (2019)

Impact of clinical domains other than arthritis on composite outcomes in psoriatic arthritis: comparison of treatment effects in the SEAM-PsA trial
od: Atul Deodhar, i dr.
Izdano: (2022-07-01)

Minimal disease activity among active psoriatic arthritis patients treated with secukinumab: 2‐year results from a multicenter, randomized, double‐blind, parallel‐group, placebo‐controlled phase III study
od: Coates, L, i dr.
Izdano: (2018)

Minimal disease activity and impact of disease in psoriatic arthritis: a Spanish cross-sectional multicenter study
od: Rubén Queiro, i dr.
Izdano: (2017-03-01)

BIOLOGIC THERAPY OF PSORIATIC ARTHRITIS
od: D.D. Gladman
Izdano: (2011-09-01)

Duration of Psoriatic Skin Disease as Risk Factor for Subsequent Onset of Psoriatic Arthritis
od: Alexander Egeberg, i dr.
Izdano: (2018-03-01)

Achieving minimal disease activity in psoriatic arthritis predicts meaningful improvements in patients’ health-related quality of life and productivity
od: Laura C. Coates, i dr.
Izdano: (2018-08-01)